×
Gain Therapeutics EBIT 2019-2025 | GANX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Gain Therapeutics ebit from 2019 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
Gain Therapeutics EBIT 2019-2025 | GANX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Gain Therapeutics ebit from 2019 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.3B
Zoetis (ZTS)
$67.7B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$46.1B
BeOne Medicines - (ONC)
$31.9B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$21.3B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.7B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$8B
Corcept Therapeutics (CORT)
$7.2B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.7B
Madrigal Pharmaceuticals (MDGL)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B